ETNB News and Press, 89bio Inc. From 12/12/22

– Data from cohorts 1-6 in the proof-of-concept study showed pegozafermin was generally well tolerated and had beneficial therapeutic effect in reducing liver fat and improving markers of liver injury, fibrosis and lipids – – Pegozafermin has the poten...

89bio press release ( NASDAQ: ETNB ): Q3 GAAP EPS of -$0.57 beats by $0.26 . As of September 30, 2022, 89bio had cash, cash equivalents, and short-term investments of $193.3 million For further details see: 89bio GAAP EPS of -$0.57 beats by $0.26

-Completed enrollment in ENLIVEN Phase 2b NASH trial with topline data expected in the first quarter of 2023- -Presented additional post-hoc exploratory analyses from the Phase 1b/2a NASH study of pegozafermin at AASLD The Liver Meeting ® 2022- -Reported additio...

- New analysis of cohort 7 data using a three-reader pathologist panel showed that 6/19 patients scored as having fibrosis stage 4 at baseline (putative F4); excluding these patients resulted in higher histological response rates in the patients with F2-F3 fibrosis than previously rep...

SAN FRANCISCO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Ma...

Summary 89bio's share price is up >100% over the past three months. The company is developing Pegozafermin, a potential therapy for NASH and SHTG. Data released by Akero for its drug Efruxifermin - which has the same mechanism of action as Pego - suggested it would meet the...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday! News moving stocks this morning include clinical trial updates, earnings reports...

SAN FRANCISCO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that Company’s Ma...

89bio ( NASDAQ: ETNB ) stock rose ~9% premarket Aug. 26 after the company presented data from a phase 2 trial of pegozafermin to treat severe hypertriglyceridemia (SHTG) at the European Society of Cardiology (ESC) Congress 2022. SHTG is a condition in which there is ...

-Results featured in a late-breaking oral presentation- -Treatment with pegozafermin demonstrated consistent and significant benefit in triglyceride (TG) reduction as well as improvements in liver fat and glycemic control- -Positive data support the advancement into a Ph...